Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002675 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy in Treating Patients With Retinoblastoma
A Phase 2 study of Retinoblastoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00002675 is a Phase 2 study of Retinoblastoma that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 50 participants, below the 589-participant average among 15 other Retinoblastoma trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00002675, a Phase 2 study of Retinoblastoma, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with retinoblastoma.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG carboplatin
- DRUG cyclophosphamide
- DRUG etoposide
- BIOLOGICAL filgrastim
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1995-05 |
| Est. Completion | 2001-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002675
The ClinicalTrials.gov registry entry for NCT00002675 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 589-participant average among 15 other Retinoblastoma trials with a reported enrollment target (92% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinoblastoma appearing as the primary indexed condition, and to 5 interventions - of which cisplatin is the first listed.
NCT00002675 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00002675 about?
NCT00002675 is a clinical study titled "Chemotherapy in Treating Patients With Retinoblastoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with retinoblastoma.
What is the current status of trial NCT00002675?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 1995-05. Estimated completion is 2001-01.
What conditions does trial NCT00002675 study?
This clinical trial studies the following conditions: Retinoblastoma.
What interventions are being tested in trial NCT00002675?
The interventions under investigation include: cisplatin (DRUG), carboplatin (DRUG), cyclophosphamide (DRUG), etoposide (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002675?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002675 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinoblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Retinoblastoma Phase II Expanded Access Clinical Trial
RECRUITING · Phase 2
-
Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma
ACTIVE NOT RECRUITING · Phase 2
-
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
COMPLETED · Phase 2
-
Chemotherapy Treatment for Children With Intraocular Germ-Line Retinoblastoma
COMPLETED · Phase 2
-
RB Liquid Biopsy Biorepository
RECRUITING
-
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.